Description: This article addresses issues of importance to HMO excess reinsurance purchasers when negotiating a reinsurance treaty.

Description: Chapter 4 analyzes, in table form, the study's claimant counts and charges in excess of deductible, broken down by deductible level, geographic region, age, gender, and subscriber vs. dependent status. From Group Medical Insurance Large Claims Database Collection and Analysis, M-HB97-1.

Description: Provider Excess is an insurance coverage offered to health care provider organizations that have a capitation agreement with a manged care organization. From Reinsurance Section News, November 2007, Issue No. 61.

Description: With the medical insurance market experiencing health care inflation of 10 to 13 percent and medical costs averaging above $8,000 per year per employee less for single employees and more for employees with families, employers are looking at alternative options. Politicians and regulators are as well.

Description: this article provides an overview of coverage and claim trends for managed care medical excess of loss insurance and reinsurance programs. it addresses features such as deductible, maximum benefit, inside limits , comprehensive versus non- comprehensive , and claims by diagnosis for commercial , Medicare and Medicaid risk. It also reviews cost containment support programs for catastrophic claims .

Description: Excess Reinsurance is a coverage purchased by insurance carriers to limit loss in a year from any one claim. This article addresses the issues when purchasing medical excess reinsurance on a medical portfolio. The most important consideration in the reinsurance purchasing decision is determining the risk objectives of the organization. The proper risk analysis by the carrier or in conjunction with its reinsurer will address the following questions: What is predictable risk versus unpredictable risk?

Description: At this presentation from Session 81PD of the SOA 1996 Colorado Springs Meeting, the panelists examine current issues involving small-employer health reinsurance programs from viewpoints of both the direct writer and the reinsurer. From the Record of the Society of Actuaries, Vol. 22, No. 2.

Description: Presented at June 1996 Spring Meeting. This panel examines current issues involving disability income reinsurance, presented from both the insurer and reinsurer viewpoints, including: recent reinsurer experience, problems facing DI writers, and uses of reinsurance.

Description: Cell and Gene Therapy (CGT) are life-changing treatments where conditions such as cancer, hemophilia, spinal muscular atrophy and blindness are being cured. These are great for individuals and society, but the treatment costs are expensive which is bad for payers and reinsurers. This article explores ways for health reinsurance actuaries to participate in the space and evaluate the risk associated with these treatments

Description: Book review of the latest edition (4th) of Life, Health, and Annuity Reinsurance by John Tiller, Jr and Denise Fagerberg Tiller